Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
He also stated a late 2014 early 2015 time frame for uplist - so either he's full of bologna, his definition of strength is different than yours, or the spin off is magically going to raise the PPS to meet minimum NASDAQ requirements.
So which one is it?
Since you are all so fond of quotes from "The Chairman's Blog":
What about the 100's of other quotes from Gerald that he went back on?
Data at the first conference, hard Lympro launch by EOY, data by EOY, wasn't ESS supposed to close today?
What makes that one singular quote so special that he wouldn't go back on that one too?
Big players don't like risking all of their money for a 100% loss - DTC chills tend to scare away anyone that depends on liquidity to get a return.
Gerald mentioned everything under the sun to shareholders. He also mentioned an R/S - so how are you so sure that its not going to happen?
He also mentioned an uplist, so how is he going to do that without an R/S?
What's next, a reverse merger? How many carrots can Gerald dangle?
They can't do that, they have no money.
What would be more interesting is if they let anyone holding for a year or more participate in a one time purchase at the same 10% original issue discount that they've been giving to their toxic financing groups. It would hurt the share price short term, but reward the long time holders in the long run.
Of course there's not going to be an issue finding additional financing - Gerald gives everyone under the sun a 10% original issue discount right off the bat and then 12% interest per year thereafter.
The problem is that he needs to cut out these bogus deals. If you can't get a decent rate on financing for a new project/acquisition then you shouldn't be undertaking it.
But instead, he gives away the farm to toxic financiers who can turn around and dump their shares on the open market in 6 months. And Gerald will have to sell more shares just to make the interest payments.
Obviously, with no revenues a certain amount of dilution is expected. But Gerald is literally growing the company on the backs of shareholders and then hanging them out to dry in the biggest way possible by diluting the daylights out of the share structure. All while he still hasn't been capable of generating revenue, and his bonuses and compensation just keeps getting bigger and bigger.
Why is that do you think?
It's not hard to lead the market when there are no other "blood tests" on the market.
They shouldn't be talking about uplisting at all.
NASDAQ traders will PUNISH this stock for these kind of fluff PR's. We'd get delisted so fast our heads would spin.
That's only about half of what they need for the first part of the option agreement. They need to pay Lonza 4 million for the first half and the 5 million later. Then they need to pay regenicin about another 4-5 million for the first half of that agreement.
They timed it that way on purpose.
They let the regular followers who track the ODD applications buy 10 million shares of dilution yesterday and they ran a PR after hours to sell the rest of the dilution to the stragglers today.
Because they have no money to purchase ESS and they killed the price movement to try and garner some money.
The last 2 days were absolute garbage.
Not to mention that they already tried to muster up some interest with that unimaginabley horrendous lympro PR. It read like "Well, we don't have the data, cost info, or pricing - but we need money for ESS so please believe us when we say that we are launching anyways without having this data to present - please buy, buy, buy."
I'm getting really tired of Gerald's garbage.
It's just too expensive, and with Lympro projections falling - shareholders will have to foot them bill. In totality this is going to cost well over 20 million dollars and probably amp up their cash burn rate.
Means more crappy financing deals and dilution to look forward too. Almost every holding AMBS has is 3-4+ years out.
Add this to the spin out, the reverse split, the uplist, etc. Gerald has promised just about every holy grail in the book (Minus the R/S) and still nothing has come from it.
Even if they split it up to the NASDAQ, they won't be able to keep it there without significant Lympro revenues.
And If they spin out diagnostics, the R&D entity will have no revenues to speak of and become a huge dilution vehicle.
After today, there's a lot more riding on Lympro revenues than there was previously.
It's not even worth asking the question, you won't get an answer based in reality.
The reality of it is, if any of that were true or even remotely closed to happening - Gerald wouldn't have dropped his pants for a 3 million dollar loan at 12% interest with a 10% purchase discount.
They would have tapped LPC knowing revenues were around the corner.
But seeing Geralds actions over the last two weeks, the only logical conclusion that anyone can come to is that they have no confidence that revenues are coming any time soon.
Would you borrow money from a loan shark when you could just use your credit card and float the debt when you know your boss has just given you a huge raise starting next quarter?
I think not.
That's how telling this new "purchase agreement" is.
Even Gerald doesn't believe we're going to uplist.
Otherwise he wouldn't have given out 12% interest, agreed to pay it quarterly, AND given them a 10% Original Issue Discount.
He would have just tapped LPC for operating/acquisition capital and then found more funding for cheaper after derisking the stock by listing on the NASDAQ.
IMO Gerald is full of garbage on this one.
Peter, Peter, Pumpkin Eater....
Sums up AMBS nicely.
You need to learn the difference between "Outstanding" and "Available"
Per the latest chairmans blog, LP002 data is now only expected some time before the end of Q4.
Like how he slid that one in there without acknowledging the previous deadline?
The problem isn't the science - its the management.
If they have enough cash on hand - then why the need for an immediate authorization doubling the authorized shares?
Because they don't have enough money to cover their increasingly heavy cash burn rate.
Their "executive compensation" is already absurd.
They're also not going to touch anything that hyper inflated its PPS to get there. Even if it rockets up and then the reverse and then the uplist -its still going to come crashing down.
Gerald should be focused much more on steady appreciation of valuation instead of a rock and roll style slam the coke down the shoot, rocket up and hope for the best.
Which is the best analogy I can think of to describe his attitude at the moment.
That particular argument has nothing to do with market cap.
There's an investor sentiment facet that you're entirely missing.
Would you pay $15 a share for a company with a history of stretching the truth, missing deadlines, and no proven product?
Yes, I'm aware of the ratios and the market cap. That's not rocket science. But this would never make it to $15 a share.
What is a mystery and may well be rocket science is how gerald brings in 750K every two years but only holds 1% (1 million dollars) of common stock.
That is not how you tie executive compensation to shareholder interests.
I am holding, and I absolutely believe it.
Much better for us to stay down here and turn that .30 into 1.00 instead of fighting a ton of short interest and trying for less than a double for $15.00.
And regardless of the share structure - no one will pay $15 a share for this even with lympro. It's simply too high a share price for a company with one product that's unproven in the market.
There is absolutely no benefit to moving this to the NASDAQ in its current state.
Reverse splits almost always result in huge price drops, especially with all of the garbage that gerald has been throwing our way lately.
Not to mention, if this hits the NASDAQ its going to be vulnerable to an infinitely larger amount of short selling.
In fact, the only reason to R/S is to increase the profitability of dilution at this point.
It's much better for the shareholders to remain on the current exchange and see if the supposed "catalysts" propel the stock higher on its own.
It's going to do us no good to over inflate our PPS to get there.
There's a reason that insiders haven't sold any shares.
Its because they have no shares to sell! Gerald has a whole 1% of the common stock and his dad has 2%.
At current prices thats what $1,000,000?
Why on earth would they sell that when Gerald can rake in 750K every 2 years by selling company shares and rewarding himself with bonuses on the investors dime?
What we have here is a serious principle-agent problem.
And now he wants us to approve a billion share increase because they don't have any more shares to pay their execs with!?
The funny thing is, this is a catch 22 - because they have almost no voting power because they have so little invested in the company.
How about we vote to curb Gerald's absurd salary bonus (mostly absurd because AMBS has ZERO positive cash flow) and instead give him a $70k salary with 200K in options that are restricted for 2 years.
Then lets see how quickly these absurd twitter comments lasts.
As an investor, I'm tired of watching the market be jerked around by Gerald.
And apparently so are the people on twitter!!!!
Right now it is a POS. It will be a POS until sales start rolling out. And it will likely be a POS for the first couple of quarters.
After those initial sales quarters, it will either be a rock star - or an un-saveable steaming pile of poo.
But its going to slowly slide down like a turd down a drainage ditch until it either hits pay dirt or splats into the sewer.
Unfortunately,
This was supposed to be a quick, down and dirty play - that never happened.
Which is also probably why we've experienced such a hard-hitting sell off.
Now my money is probably going to be tied up for 6 months to a year or more, but I'm fairly certain it will recoup and profit.
I might have to just stop watching this one day to day - which is 100% against my normal rationale.
The day to day trading just doesnt really matter at this level. With a signed partner and a product that will hit the market within the next few months, its going to hit the bottom semi-soon and from there its all about sales.
I just didn't want to have to wait that long to get my capital back out.
Or it means that they have no money and no partner and will need to dilute.
SERIOUSLY how many times have you seen a stock do an R/S and double the A/S and have it turn out well!
Gerald is turning this into garbage.
Anyone know when the next blog post is supposed to be?
I thought I heard today, but I cant remember if that was a definitive date or not.
How is it not beneficial if they can integrate the other bio indicators?
I don't believe the goal is to predict wether or not one will get AD, its whether or not one has AD - be it early onset or not - in order to effectively be able to determine eligibility for further clinical tests or get them into the proper course of treatment as early as possible.
You totally sidestepped my question.
I am sorry for your personal loss, AD is a very difficult thing for everyone involved and I wish you the best and your family the best.
This is practically a non-issue for AMBS at this point. Its going to be phased in for 9 years, and initially only be focused at diagnosing critical illnesses - and excludes placing regulations on tests where there is no alternative testing method.
IMO this excludes AMBS in almost every way.
Quote from the article:
Personally, IMO -
Gerald might be good at running a company, probably will even take AMBS to the next level and beyond.
But as an investor relations spokespiece - he sucks. He shouldn't be giving timelines that he can't hit, posting tweets or letting things be tweeted that are inaccurate - like letting his partner at brewers post the incorrect time of his ESPN radio debut, and leave it uncorrected - and MOST of all, he shouldnt treat the investor community like they all have MD's.
I like to think of myself as pretty quick witted - but I know very little about medical statistics or clinical trials - it took me a few reads to notice the significant detail that the 80% S&S was the result of a single marker, and then understand the significance.
Had they come out and said that, and then placed an emphasis on what that means very clearly at the conference and then again in the PR, we might have sustained some of those gains and minimized the money runner manipulation that fed/turned into panic selling.
I think there needs to be a lot more effort put into their public relations.
They are indeed relevant.
But only based on one biomarker - which is made clear in the PR.
80% S&S from one biomarker is outstanding when they have more that they are going to integrate into the test.
Aren't you supposed to know your science?
It is also important to note that the 80% S&S was achieved using only 1 bio marker...
Wait until they integrate the others....
I like the pipeline. But I think Gerald (the main heavy hitter) is an investor relations idiot.
You cant keep breaking promises and deadlines to investors and expect nothing to happen.
Agreed.
Part of me thinks this might just be a case of mass paranoia and 1 or 2 rabble rousers feeding on delayed data presentation.
Even the bad data from the previous tests was PR'd one at a time.
Yet, this time there's nothing.
I seriously cannot find any information of what - if any - data was presented at the summit.
And this appears to be a prevalent problem. Everyone is weighing in and only 10% of the people even watched the broadcast.
Is there ANY data ANYWHERE?
Half of the boards are saying data is delayed, other half are claiming bad data was presented.
What exactly is the deal?
Apparently it was on, but the wrong time was put up.
There are follow up tweets with quotes from the radio clip - I assume.
Should have been worth a time correction tweet from Gerald.
While I partially agree with you, I think there are also several offshoot sectors as well. For example the legal sector.
I bet someone involved in the Donald Sterling case would eat this test up.
Remind me how many shares there were short again?
70 million?
Whoopsie Daisy
MNKD - anyone looking at this one?